235 related articles for article (PubMed ID: 28291086)
1. Opioid-type Respiratory Depressant Side Effects of Cebranopadol in Rats Are Limited by Its Nociceptin/Orphanin FQ Peptide Receptor Agonist Activity.
Linz K; Schröder W; Frosch S; Christoph T
Anesthesiology; 2017 Apr; 126(4):708-715. PubMed ID: 28291086
[TBL] [Abstract][Full Text] [Related]
2. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model.
Christoph T; Raffa R; De Vry J; Schröder W
Pharmacol Res Perspect; 2018 Dec; 6(6):e00444. PubMed ID: 30519474
[TBL] [Abstract][Full Text] [Related]
4. Respiratory Effects of the Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human Volunteers.
Dahan A; Boom M; Sarton E; Hay J; Groeneveld GJ; Neukirchen M; Bothmer J; Aarts L; Olofsen E
Anesthesiology; 2017 Apr; 126(4):697-707. PubMed ID: 28291085
[TBL] [Abstract][Full Text] [Related]
5. Functional Profile of Systemic and Intrathecal Cebranopadol in Nonhuman Primates.
Ding H; Trapella C; Kiguchi N; Hsu FC; Caló G; Ko MC
Anesthesiology; 2021 Sep; 135(3):482-493. PubMed ID: 34237134
[TBL] [Abstract][Full Text] [Related]
6. Cebranopadol : a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors.
Sałat K; Jakubowska A; Kulig K
Expert Opin Investig Drugs; 2015 Jun; 24(6):837-44. PubMed ID: 25865744
[TBL] [Abstract][Full Text] [Related]
7. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
8. Nociceptin/orphanin FQ opioid peptide (NOP) receptor and µ-opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain.
Schiene K; Schröder W; Linz K; Frosch S; Tzschentke TM; Jansen U; Christoph T
Eur J Pharmacol; 2018 Aug; 832():90-95. PubMed ID: 29753041
[TBL] [Abstract][Full Text] [Related]
9. Antihyperalgesic, Antiallodynic, and Antinociceptive Effects of Cebranopadol, a Novel Potent Nociceptin/Orphanin FQ and Opioid Receptor Agonist, after Peripheral and Central Administration in Rodent Models of Neuropathic Pain.
Tzschentke TM; Linz K; Frosch S; Christoph T
Pain Pract; 2017 Nov; 17(8):1032-1041. PubMed ID: 28112482
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain.
Sałat K; Furgała A; Sałat R
Inflammopharmacology; 2018 Apr; 26(2):361-374. PubMed ID: 29071457
[TBL] [Abstract][Full Text] [Related]
11. Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic.
Calo G; Lambert DG
Br J Anaesth; 2018 Nov; 121(5):1105-1114. PubMed ID: 30336855
[TBL] [Abstract][Full Text] [Related]
12. Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors.
Tzschentke TM; Linz K; Koch T; Christoph T
Handb Exp Pharmacol; 2019; 254():367-398. PubMed ID: 30927089
[TBL] [Abstract][Full Text] [Related]
13. Cebranopadol: novel dual opioid/NOP receptor agonist analgesic.
Raffa RB; Burdge G; Gambrah J; Kinecki HE; Lin F; Lu B; Nguyen JT; Phan V; Ruan A; Sesay MA; Watkins TN
J Clin Pharm Ther; 2017 Feb; 42(1):8-17. PubMed ID: 27778406
[TBL] [Abstract][Full Text] [Related]
14. Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist.
Lambert DG; Bird MF; Rowbotham DJ
Br J Anaesth; 2015 Mar; 114(3):364-6. PubMed ID: 25248647
[No Abstract] [Full Text] [Related]
15. Limited potential of cebranopadol to produce opioid-type physical dependence in rodents.
Tzschentke TM; Kögel BY; Frosch S; Linz K
Addict Biol; 2018 Sep; 23(5):1010-1019. PubMed ID: 28944554
[TBL] [Abstract][Full Text] [Related]
16. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
17. Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.
Ko MC; Woods JH; Fantegrossi WE; Galuska CM; Wichmann J; Prinssen EP
Neuropsychopharmacology; 2009 Aug; 34(9):2088-96. PubMed ID: 19279568
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study.
Göhler K; Sokolowska M; Schoedel KA; Nemeth R; Kleideiter E; Szeto I; Eerdekens MH
J Clin Psychopharmacol; 2019; 39(1):46-56. PubMed ID: 30531478
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys.
Saccone PA; Zelenock KA; Lindsey AM; Sulima A; Rice KC; Prinssen EP; Wichmann J; Woods JH
J Pharmacol Exp Ther; 2016 Apr; 357(1):17-23. PubMed ID: 26801398
[TBL] [Abstract][Full Text] [Related]
20. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice.
Khroyan TV; Zaveri NT; Polgar WE; Orduna J; Olsen C; Jiang F; Toll L
J Pharmacol Exp Ther; 2007 Feb; 320(2):934-43. PubMed ID: 17132815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]